Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value
暂无分享,去创建一个
Martin Schostak | Kurt Miller | Mark Schrader | Carsten Kempkensteffen | Frank Christoph | Steffen Weikert | K. Miller | M. Schrader | M. Schostak | Stefan Hinz | Hans Krause | H. Krause | C. Kempkensteffen | S. Hinz | F. Christoph | A. Magheli | S. Weikert | Ahmed Magheli
[1] P. Krammer,et al. Tumor Immunology , 2018, Medical Immunology.
[2] W. Park,et al. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[3] J. Lam,et al. Adjuvant treatment for renal cell carcinoma , 2006, Expert opinion on pharmacotherapy.
[4] V. Dixit,et al. SMAC Negatively Regulates the Anti-apoptotic Activity of Melanoma Inhibitor of Apoptosis (ML-IAP)* , 2002, The Journal of Biological Chemistry.
[5] A. MacKenzie,et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.
[6] C. Dinney,et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. , 1998, The Journal of urology.
[7] J C Reed,et al. IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.
[8] A. Belldegrun,et al. The changing natural history of renal cell carcinoma. , 2001, The Journal of urology.
[9] F. McGovern,et al. Renal-cell carcinoma. , 2005, The New England journal of medicine.
[10] G. Salvesen,et al. Neutralization of Smac/Diablo by Inhibitors of Apoptosis (IAPs) , 2004, Journal of Biological Chemistry.
[11] John Calvin Reed,et al. Endogenous Inhibitors of Caspases , 1999, Journal of Clinical Immunology.
[12] J C Reed,et al. Dysregulation of apoptosis in cancer. , 1998, The cancer journal from Scientific American.
[13] R. Figlin,et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. , 2003, The Journal of urology.
[14] J. Kaouk,et al. Cryotherapy: clinical end points and their experimental foundations. , 2006, Urology.
[15] W. Du,et al. Livin promotes Smac/DIABLO degradation by ubiquitin–proteasome pathway , 2006, Cell Death and Differentiation.
[16] G. Núñez,et al. Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.
[17] G. Salvesen,et al. Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.
[18] D. Vaux,et al. The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3– and caspase 9–interacting sites , 2002, The Journal of cell biology.
[19] M. Zelefsky,et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Tamai,et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity , 2001, Nature Cell Biology.
[21] H E Gabbert,et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas , 2004, British Journal of Cancer.
[22] Daniel A. Colón-Ramos,et al. Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition , 2002, Nature Cell Biology.
[23] R. Figlin,et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. , 2000, The Journal of urology.
[24] Kotaro Mizuno,et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. , 2004, Oncology reports.
[25] R. Figlin,et al. Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Vaux,et al. Cell death regulation by the mammalian IAP antagonist Diablo/Smac , 2002, Apoptosis.
[27] Alamdari,et al. Follow‐up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy , 1999, BJU international.
[28] J. Ordovás,et al. Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. , 1998, Methods in molecular biology.
[29] Xuebiao Yao,et al. Direct Interaction between Survivin and Smac/DIABLO Is Essential for the Anti-apoptotic Activity of Survivin during Taxol-induced Apoptosis* , 2003, Journal of Biological Chemistry.
[30] R. Figlin,et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.
[31] Xiaodong Wang,et al. Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.
[32] J. Mclaughlin,et al. Epidemiologic aspects of renal cell cancer. , 2000, Seminars in oncology.
[33] P. Mulders,et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. , 2006, The Journal of urology.
[34] E. Lopez Hänninen,et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. , 1993, European journal of cancer.
[35] Hiroyuki Nakanishi,et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Yuri Lazebnik,et al. Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease That Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction* , 2002, The Journal of Biological Chemistry.
[37] P. Jiang,et al. Novel link between E2F1 and Smac/DIABLO: proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1 , 2006, Nucleic acids research.
[38] Yaqoub Ashhab,et al. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. , 2004, Seminars in cancer biology.
[39] R. Korneluk,et al. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. , 2000, Genomics.
[40] M. Resnick,et al. A new protocol for the followup of renal cell carcinoma based on pathological stage. , 1995, The Journal of urology.